The efficacy of dual blockade targeting TIGIT and PD-1 is being assessed in the phase III STAR-221 trial (NCT05568095) in the first-line setting for GC, as well as in a cohort of metastatic MSI-H tumors from the phase II basket TIRACAN trial (NCT05483400) (Table 5). This evidence concerns the gene TIGIT and gastric cancer.